[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1, 1973

L-m-Tyrosine and Parkinsonism

Author Affiliations

Brookhaven National Laboratory Upton, NY

JAMA. 1973;223(1):83. doi:10.1001/jama.1973.03220010069038
Abstract

To the Editor.—  Administrations of levodopa, which generates the primary catecholamine dopamine, or of the tertiary catecholamine apomorphine hydrochloride, have improved the symptoms of parkinsonism.1,2 L-m-tyrosine generates the primary amine m-tyramine, which does not have a catechol configuration, not even an equivalent one. In experimental animals, however, L-m-tyrosine had induced manifestations similar to those induced by levodopa, which differed somewhat from those of apomorphine.3,4 L-m-tyrosine was, therefore, proposed for the treatment of parkinsonism.These considerations produced two reasons for testing the effects of L-m-tyrosine on the symptoms of parkinsonism: (1) to determine whether or not the catechol moiety is necessary for the therapeutic actions of amines in this disease, and (2) to determine whether or not reactions of animals to a new drug can be extrapolated into therapy on the basis of their being similar to those of an

×